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␣-Thrombin has two separate electropositive binding exosites
(anion binding exosite I, ABE-I and anion binding exosite II, ABE-II)
that are involved in substrate tethering necessary for efficient catalysis.
␣-Thrombin catalyzes the activation of factor V and factor VIII following discrete proteolytic cleavages. Requirement for both anion binding
exosites of the enzyme has been suggested for the activation of both
procofactors by ␣-thrombin. We have used plasma-derived ␣-thrombin, ␤-thrombin (a thrombin molecule that has only ABE-II available),
and a recombinant prothrombin molecule rMZ-II (R155A/R284A/
R271A) that can only be cleaved at Arg320 (resulting in an enzymatically active molecule that has only ABE-I exposed, rMZ-IIa) to ascertain the role of each exosite for procofactor activation. We have also
ⴚ
employed a synthetic sulfated pentapeptide (DY(SOⴚ
3 )DY(SO3 )Q, designated D5Q1,2) as an exosite-directed inhibitor of thrombin. The
clotting time obtained with ␤-thrombin was increased by ⬃8-fold,
whereas rMZ-IIa was 4-fold less efficient in promoting clotting than
␣-thrombin under similar experimental conditions. ␣-Thrombin
readily activated factor V following cleavages at Arg709, Arg1018, and
Arg1545 and factor VIII following proteolysis at Arg372, Arg740, and
Arg1689. Cleavage of both procofactors by ␣-thrombin was significantly
inhibited by D5Q1,2. In contrast, ␤-thrombin was unable to cleave
factor V at Arg1545 and factor VIII at both Arg372 and Arg1689. The
former is required for light chain formation and expression of optimum factor Va cofactor activity, whereas the latter two cleavages are a
prerequisite for expression of factor VIIIa cofactor activity. ␤-Thrombin was found to cleave factor V at Arg709 and factor VIII at Arg740,
albeit less efficiently than ␣-thrombin. The sulfated pentapeptide
inhibited moderately both cleavages by ␤-thrombin. Under similar
experimental conditions, membrane-bound rMZ-IIa cleaved and activated both procofactor molecules. Activation of the two procofactors
by membrane-bound rMZ-IIa was severely impaired by D5Q1,2. Overall the data demonstrate that ABE-I alone of ␣-thrombin can account
for the interaction of both procofactors with ␣-thrombin resulting in
their timely and efficient activation. Because formation of meizothrombin precedes that of ␣-thrombin, our findings also imply that
meizothrombin may be the physiological activator of both procofactors in vivo in the presence of a procoagulant membrane surface during
the early stages of coagulation.
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Blood clotting involves a multitude of proteins, which act in concert in
response to vascular injury to produce the procoagulant enzyme thrombin,
which in turn is responsible for the generation of the fibrin plug (1). The two
procoagulant enzymatic complexes (i.e. intrinsic tenase and prothrombinase) that are critical for thrombin formation are similar in structure and
composed of an enzyme, a cofactor, and the substrate associated on a cell
surface in the presence of divalent metal ions. The intrinsic tenase complex
is composed of the enzyme, factor IXa, and the cofactor, factor VIIIa, associated on the cell membrane in the presence of divalent metal ions. Similarly, the prothrombinase complex is composed of the enzyme, factor Xa,
and the cofactor, factor Va, associated on a cell surface in the presence of
divalent metal ions. Although both enzymes factor IXa and factor Xa alone,
can activate factor X and prothrombin, respectively, their catalytic efficiencies are poor, and the overall reactions are incompatible with survival and
the arrest of bleeding. Incorporation of the protein cofactor into both complexes results in a substantial increase in the catalytic efficiency of both
enzymes, for cleavage and activation of their substrates insuring normal
hemostasis (2– 8). The increase in the overall enzymatic reaction is attributed to a large increase in the kcat of the reactions, which in turn is solely
attributed to the interaction of the cofactor molecules with both the membrane-bound enzyme and the membrane-bound substrate. Thus, the activities of the prothrombinase complex, as well as the intrinsic tenase complex,
are limited by the presence of the two soluble, non-enzymatic cofactors,
factor Va and factor VIIIa.
The procofactors, factor V and factor VIII, do not interact with the components of prothrombinase and intrinsic tenase, respectively. Proteolytic
processing of factor V by ␣-thrombin at Arg709, Arg1018, and Arg1545, results
in the production of the active cofactor, factor Va, which consists of a heavy
chain (Mr 105,000) and a light chain (Mr 74,000), and factor Va is required
for the interaction of the cofactor with the members of prothrombinase
(9 –11) (Fig. 1). Similarly, factor VIII is activated following proteolysis by
␣-thrombin at Arg372, Arg740, and Arg1689 (12–15) (Fig. 1). Although cleavages at Arg372 and Arg1689 by ␣-thrombin are required for activation of
factor VIII and expression of full procoagulant activity, requirement for
cleavage at Arg740 for expression of activity has not yet been rigorously
established (16 –18). Both procofactors have in common the fact that all
activating cleavage sites (with the exception of cleavage at Arg1018 in factor
V) are preceded by a region rich in acidic amino acids that contain sulfated
tyrosines (19) (Fig. 2). These regions (a1, a2, and a3 in factor VIII and b1 and
b2 in factor V) have been reported to be required for appropriate interaction of both procofactors with ␣-thrombin. Although the exact location of
the six sulfated tyrosines in factor VIII has been confirmed independently
by several laboratories (20 –22), confirmation of the exact positions of sulfated tyrosines in factor V has not been yet reported. However, earlier data
have shown that sulfation is important for factor V activation by ␣-thrombin and cofactor function (23, 24). These residues in factor V and factor VIII
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FIGURE 1. Activation of factor V and factor VIII by ␣-thrombin. Factor V is composed of 2196 amino acids. The molecule has three A domains (A1, A2, and A3), a connecting B region,
and two C domains (C1 and C2). Factor V is activated following three sequential cleavages by ␣-thrombin at Arg709, followed by Arg1018, with Arg1545 being the last to occur (8, 9).
These cleavages release the active cofactor composed of a heavy chain of Mr 105,000 and a light chain of Mr 74,000, and two activation fragments of Mr 71,000 and Mr 150,000. The
amino acid regions preceding cleavages at Arg709 and Arg1545 have a high content in acidic amino acids (black regions, b1 and b2; amino acid composition is detailed in Fig. 2). Factor
VIII is composed of 2332 amino acids. The molecule has three A domains (A1, A2, and A3), a B region, and two C domains (C1 and C2). Factor VIII is activated following three cleavages
by ␣-thrombin at Arg372, Arg740, and Arg1689. Cleavage at Arg740 produces a Mr 90, 000 heavy chain, whereas cleavage at Arg372 is required for activation because it appears to expose
a cryptic factor IXa-binding exosite on the cofactor. Cleavage at Arg1689 is also required for activation and the release of the Mr 74,000 light chain of the cofactor. The amino acid
regions preceding all three cleavages have a high content in acidic amino acids (black regions, a1, a2, and a3; amino acid composition is detailed in Fig. 2).

FIGURE 2. Acidic regions preceding the activating cleavage sites. The acidic regions preceding the activating cleavages in factor V and factor VIII are compared and aligned using
the ALIGN module from ExPASy (74). The dark arrows show the ␣-thrombin cleavage sites in each amino acid stretch (the specific amino acids are identified by bold italic and are
underlined). Panel A represents the amino acid region around the a1 domain of factor VIII (Tyr346 is underlined) with the corresponding portion from factor V (amino acid residues
307–330). In panel B the region around the a2 domain from factor VIII (containing Tyr718, Tyr719, and Tyr723) is compared with the amino acid region containing domain b1 from factor
V (possessing Tyr665, Tyr696, and Tyr698). Panel C depicts the comparison between the amino acid region around the domain a3 from factor VIII (containing Tyr1680) with the amino acid
region around domain b2 from factor V (containing Tyr1494, Tyr1510, and Tyr1515). The colon symbol represents identity between the two amino acid sequences.

satisfy all the criteria for sulfation and may thus be required for proper
attachment and function of tyrosyl sulfotransferases (25–27).
Prothrombin and ␣-thrombin have two distinct electropositive binding exosites (anion binding exosite I, ABE-I, and anion binding exosite
II, ABE-II)2 that are responsible for the functions of the molecules (28 –
2

The abbreviations used are: ABE-I, anion binding exosite I; ABE-II, anion binding exosite
II; APC, activated protein C; TM, thrombomodulin; PS, L-␣-phosphatidylserine; PC,
L-␣-phosphatidylcholine; PCPS, small unilamellar phospholipids vesicles composed
of 75% PC and 25% PS (w/w); rMZ-II, recombinant prothrombin with the substitutions
Arg155 3 Ala, Arg284 3 Ala, and Arg271 3 Ala); D5Q, pentapeptide Asp-Tyr-Asp-Tyr⫺
Gln; D5Q1,2, disulfated pentapeptide Asp-Tyr(SO⫺
3 )-Asp-Tyr(SO3 )-Gln; TPCK, L-1-tosylamido-2-phenylethyl chloromethyl ketone.
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37). ABE-I has been implicated in binding to thrombomodulin (38),
fibrinogen (39), heparin cofactor II (40), PAR1 (41), and the COOHterminal hirudin peptides (42). ABE-II has been implicated in the interaction of ␣-thrombin with heparin cofactor II (40), protease nexin (43),
and antithrombin III (40). Both ABEs were found to be involved in the
activation of factors V and VIII (32, 33). The procofactor, factor V,
interacts with immobilized ␣-thrombin through ABE-I but with a lower
affinity than factor Va (28 –31, 44).
Proexosite I of prothrombin, which is present in a low affinity state on
the molecule, is fully exposed following activation and formation of
thrombin, and the affinity for its ligands increases by ⬃100-fold (31, 37).
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Cleavage at Arg320 in prothrombin resulting in meizothrombin generation is required and sufficient for the formation of the active site of
␣-thrombin and complete exposure of ABE-I of the molecule (45–51).
However, meizothrombin does not have a fully exposed ABE-II (50 –
56). Optimal exposure of this exosite, which is partially covered by fragment 2 of prothrombin, requires cleavage at Arg271 (51–57). Hence, most
functions associated with ABE-II of ␣-thrombin are impaired in meizothrombin. For this reason, meizothrombin has reduced clotting activity
(48).
Autolysis of native human ␣-thrombin, or controlled proteolysis of
the enzyme by TPCK-trypsin at Arg67 and Arg77 results in the formation
of ␤-thrombin (58 – 61). This conversion is responsible for a dramatic
but differential loss of several of ␣-thrombin’s enzymatic properties. For
example, while ␤-thrombin conserves its amidolytic activity, it loses its
fibrinogen clotting activity and the ability to activate protein C in the
presence of thrombomodulin. The loss of these activities is attributed to
the removal of eleven amino acids from the B chain of ␣-thrombin
(amino acid residues 63–73) containing critical residues from ABE-I of
␣-thrombin and resulting in a spatial rearrangement of the remaining
amino acids that make up ABE-I. It is quite surprising that the active site
histidine, which is contained within the 62-amino acid peptide moiety
attached to the rest of the ␤-thrombin molecule by non-covalent bonds,
retains its precise role during catalysis. Whereas the active site of the
enzyme appears to be only subtly changed, ABE-I-dependent functions
of ␤-thrombin are dramatically impaired. Thus, the ␤-thrombin and
meizothrombin molecules provide natural probes to examine the functions of the two ABEs independently. The present study utilizes these
two thrombin derivatives to elucidate the importance of each ABE in the
activation of factor V and factor VIII.

EXPERIMENTAL PROCEDURES
Materials, Reagents, and Proteins—Diisopropyl fluorophosphate,
Hepes, Trizma (Tris base), Coomassie Blue R-250, hirudin 55– 65 (sul54 – 65
fated hirudin, Hir55–65 (SO⫺
, non-sulfated
3 )), hirudin 54 – 65 (Hir
hirudin), and factor V-deficient plasma were purchased from Sigma.
The secondary anti-mouse and anti-sheep IgG coupled to peroxidase
were from Southern Biotechnology Associates Inc. (Birmingham, AL).
L-␣-Phosphatidylserine (PS) and L-␣-phosphatidylcholine (PC) were
from Avanti Polar Lipids (Alabaster, AL). The chemiluminescent reagent ECL⫹ and heparin-Sepharose were from Amersham Biosciences.
Normal reference plasma, prothrombin-deficient plasma, and the chromogenic substrate Spectrozyme-TH were from American Diagnostica
Inc. (Greenwich, CT). The thromboplastin reagent (Recombiplastin)
for the clotting assays was purchased from Beckman (Fullerton, CA).
The fluorescent thrombin inhibitor dansylarginine-N-(3-ethyl-1,5pentanediyl)amide, human factor Xa, human thrombin, human prothrombin, the monoclonal antibody ␣hFV#1 coupled to Sepharose, and
polyclonal monospecific antibody to prothrombin, were from Hematologic Technologies Inc. (Essex Junction, VT). Human ␤-thrombin was
prepared as described (62) and was purchased from Hematologic Technologies Inc. The B chain of the ␤-thrombin molecule was cleaved at
Arg62 and Arg73 (residues numbered consecutively from the beginning
of the B chain of thrombin (63)) or Arg67 and Arg77 in chymotrypsin
numbering (64, 65) as determined by NH2-terminal sequencing (not
shown). The ␤-thrombin used in this study is composed of amino acids
1– 62 attached to the rest of the molecule (amino acid residues 73–259)
by non-covalent bonds as previously suggested (58, 62). The two monoclonal antibodies to human factor V (against the heavy and light chains
of the cofactor, i.e. ␣HFVHC#17 and ␣HFVLC#9, respectively) were provided by Dr. Kenneth G. Mann (Dept. of Biochemistry, University of
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Vermont, Burlington VT) and have been extensively characterized (66,
67). The pentapeptide DYDYQ (D5Q) that was previously shown to
inhibit prothrombinase activity and delay factor V activation (68) as well
as its sulfated version (D5Q1,2) were custom synthesized by New England Peptide Inc. (Gardner, MA) and by American Peptide Company
(Sunnyvale, CA) respectively, purified by high-performance liquid
chromatography, and characterized by mass-spectrometry/liquid chromatography. Initial experiments were performed with D5Q1,2 synthesized and characterized in the laboratory of Dr. Satya Yadav at the
Cleveland Clinic Foundation. The pentadecapeptide P15H, containing
sequence 337–351 of factor Va heavy chain, was also custom synthesized and purchased from New England Peptide Inc. Peptides were usually dissolved in water to a given concentration and used immediately.
Although no problem was encountered when working with the sulfated
peptide, it is noteworthy that D5Q was highly insoluble at concentrations of ⬎5 mM. D5Q precipitated over time when incubated on ice.
Thus, for all experiments D5Q was made fresh and kept at room temperature. Recombinant prothrombin rMZ-II that has only one cleavage
site for factor Xa (prothrombin with the substitution Arg155 3 Ala,
Arg284 3 Ala, and Arg271 3 Ala) was prepared and purified as described
(48, 69, 70). Recombinant purified human factor VIII was provided by
Dr. Lisa Regan (Bayer Incorporation, Berkeley, CA). Human factor V
was purified using methodologies previously described employing the
monoclonal antibody ␣hFV#1 coupled to Sepharose (71). The cofactor
activity of the factor Va preparations was measured by a clotting assay
using factor V-deficient plasma and standardized to the percentage of
control as described (71). Phospholipids vesicles composed of 75% PC
and 25% PS (referred to as PCPS vesicles throughout the manuscript)
were prepared as previously described (72). The concentration of phospholipids vesicles was determined by phosphorous assay as described
earlier and is given as the concentration of inorganic phosphate (73).
Molecular Dynamics Simulation of the Peptides—The initial threedimensional models of D5Q and D5Q1,2 were built using Pymol.3 The
parameter set used was a modified version of GROMOS-87 (75), implemented in the GROMACS package (76 –78) as “ffgmx.” A topology file
for D5Q1,2 was generated by the PRODRG server (79). The “pdb2gmx”
program from the GROMACS package was used to generate the topology file for D5Q. For the molecular dynamics simulations, the peptide
D5Q or D5Q1,2, was placed in a water box by setting the distance
between the box walls and the peptide to 10 Å. Initial velocities for
atoms were taken from the Maxwellian distribution at 300 K. As solvent
we used the single point charge water model (80). Na⫹ ions were added
using the “genion” program from the GROMACS package (76 –78) to
keep the system neutral, by replacing water molecules with Na⫹ ions.
Bonds were constrained using the LINCS algorithm (81).
Energy minimization was carried out with the steepest-descent
method with the initial step set to 0.1 Å. For the neighbor search, the
“grid” option was used, and the list update frequency was set to 10.
Periodic boundary conditions were employed in all three dimensions.
The cutoff distance for the short-range neighbor list was set to 9 Å. Long
range electrostatic interactions were treated using the particle mesh
Ewald summation method (82, 83). Ewald summation was performed in
all thee dimensions. Grid dimension for the fast Fourier transforms was
set to 1.6 Å, and the interpolation order was set to 4. Bonds were not
constrained during energy minimization. Position restraint molecular
dynamics simulation was performed using the “md” integrator with all
bonds constrained. The heavy atoms from the peptide were restrained
to move around their initial position with a harmonic oscillator func3

W. L. DeLano (2002) DeLano Scientific, San Carlos, CA.
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tion. The integration step was set to 2 fs. Position restraint was run for
20 ps. Long range electrostatic interactions were calculated as described
in the energy minimization step. The NPT ensemble (constant number
of atoms, constant pressure, and constant temperature) was used in all
simulations as well as a reference temperature of 300 K. Constant
pressure was maintained, i.e. reference pressure of 1 bar, using
Parrinello-Rahman isotropic pressure coupling with the compressibility set to 4.5 ⫻ 10⫺5 bar⫺1. All parameters for the molecular
dynamics simulations were as described in the position restraint
molecular dynamic simulations except that the heavy atoms were
allowed to move freely. The peptide, solvent, and the Na⫹ ions were
separately coupled to a Berendsen thermostat (84) with a reference
temperature of 300 K. The molecular dynamics simulation time was
set to 50 ns. Distance analysis was performed using the “g_dist”
analysis program from the GROMACS package.
Meizothrombin Activation—For experiments performed with rMZII, reaction mixtures composed of 30 M PCPS, 10 nM FVa, 0.5 nM FXa,
and 1.4 M rMZ-II were incubated in buffer composed of 20 mM Tris,
0.15 M NaCl, pH 7.4 (Tris-buffered saline), 5 mM Ca2⫹ at ambient temperature. Activation of rMZ-II was monitored by removing aliquots of
the reaction mixture at various times and diluting to 50 nM rMZ-II into
a quench buffer in a 96-well plate. A 50 nM dilution of ␣-thrombin was
also incubated into quench buffer for comparison. Both samples were
incubated with Spectrozyme-TH, and the optical density was determined at 405 nm. Under these conditions, it was established that a
7.5-min incubation of rMZ-II with prothrombinase yielded optimally
active meizothrombin (rMZ-IIa). In various experiments the level of
activity of rMZ-IIa obtained with respect to cleavage of Spectrozyme-TH was 92–118% of the activity obtained with a similar concentration of ␣-thrombin. These findings are in agreement with previous data showing the potency of rMZ-IIa against a chromogenic
substrate measuring thrombin activity (85). Thus, in all experiments
described, rMZ-II was incubated with 0.5 nM prothrombinase for 7.5
min followed by the addition of a 2-fold excess of tick anticoagulant
protein (1 nM) to stop the reaction. Prior to all experiments using rMZII, 50 nM rMZ-IIa and 50 nM thrombin were always compared for activity by chromogenic substrate to ensure that activation occurred, and
rMZ-IIa was used immediately following activation.
Thrombin Time Assays—Peptides were screened for their capability
to inhibit thrombin’s ability to generate a fibrin clot in a thrombin assay
using normal hemostasis reference plasma. Various concentrations of
peptide were incubated with 20 nM thrombin for 5 min at ambient
temperature in a final volume of 75 l and then mixed with an equal
volume of plasma. Final concentration of the enzyme was 10 nM in all
assays. The reaction mixture was incubated in a water bath set to 37 °C
and monitored by manually tilting the tube until a fibrin clot was
observed. All reactions were performed in triplicate, and the various
clotting times were plotted as time (seconds) versus final peptide concentration (micromolar).
Prothrombin Clotting Assays—To screen the ability of the peptides to
inhibit prothrombin function in whole plasma a clotting assay using
prothrombin-deficient plasma was employed. To determine the optimal concentration of prothrombin to be used in these assays, a standard
curve was first generated using prothrombin concentrations in a 350 nM
to 2.5 nM range. The clotting assay was performed as follows: 50 l of
prothrombin-deficient plasma was added to 100 l of thromboplastin
reagent, and the reaction was started by the addition of 50 l of sample.
The reaction was incubated at 37 °C in a water bath, and the time to clot
generation was measured. Under these conditions, 25 nM prothrombin
(final concentration in the assay) was found to produce an average clot-
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ting time of 27 s, which was located on the linear portion of the standard
curve. This concentration of prothrombin was used for all clotting
assays. Peptides were incubated with prothrombin for 5 min at ambient
temperature before being used in the clotting assay. All experiments
were performed at least in triplicate.
Gel Electrophoresis and Western Blotting—SDS-PAGE analyses
were performed using 4 –12% gradient gels (for factor V analyses) or
5–15% (for factor VIII analyses) according to the method of Laemmli
(86). In several experiments, proteins were transferred to polyvinylidene difluoride membranes according to the method described by
Towbin et al. (87). After transfer to nitrocellulose, factor V heavy and
light chain(s) were detected using the appropriate monoclonal and
polyclonal antibodies. Immunoreactive fragments were visualized
with chemiluminescence.
Inhibition of Factor V and Factor VIII Cleavage by D5Q and
D5Q1,2—The ability of the peptides to inhibit ␣-thrombin, ␤-thrombin, and rMZ-IIa to cleave and activate the cofactors, was assessed over
time by SDS-PAGE. Peptides or an equivalent amount of Tris-buffered
saline with Ca2⫹ were incubated with the enzymes for 5 min at ambient
temperature. Reaction mixtures containing 500 nM cofactor (plasmaderived human factor V or recombinant human factor VIII) were
diluted in Tris-buffered saline plus Ca2⫹. An aliquot was removed at
zero time for analysis by SDS-PAGE. In experiments with rMZ-IIa, 20
M PCPS was also added into the reaction mixtures. The final concentrations of peptides and various enzymes in the mixtures were 100 M
and 2 nM, respectively, or as indicated. Time courses were started by the
addition of the enzyme species and peptide mixtures, and samples were
removed at time points described in the legend to the figures. In the case
of all the factor VIII activation experiments, 10 g of protein was
removed per time point, and gels were stained by Coomassie Brilliant
Blue. In the case of all factor V activation experiments, 1 g of protein
was removed per time point for gel electrophoresis. Gels were transferred to polyvinylidene difluoride membranes followed by immunoblotting with specific monoclonal antibodies. In all experiments, reactions were performed simultaneously in the presence and in absence of
peptides.
Immunoblotting of Whole Plasma Samples—The modified clotting
assay used in our studies to compare the efficiency of prothrombin and
meizothrombin for clot formation was described in details elsewhere
(66). Using the same methodology and prothrombin-deficient plasma,
the capability of rMZ-II to induce clotting was also assayed. In this latter
case, plasma was diluted 10-fold in a CaCl2-containing buffer, and 140
nM rMZ-II was added prior to the initiation of clotting by the addition of
PCPS vesicles. At selected time intervals before and after clot formation
given in the legend to the figures, samples were withdrawn and analyzed
by SDS-PAGE following by immunoblotting with monoclonal antibodies to factor V or with a monospecific polyclonal antibody to prothrombin. Immunoreactive fragments were visualized with chemiluminescence. The films were scanned with a Lexmark printer/scanner; the final
images were captured as TIFF files and analyzed by densitometry using
the software UN-SCAN-IT gel (Silk Scientific, Orem, UT).

RESULTS
Thrombin Derivatives and Thrombin Time—Meizothrombin is an
intermediate formed during prothrombin activation that has enzymatic
activity. Its properties are difficult to study because of autocatalytic
events resulting in its instability. Recombinant meizothrombin that has
been mutated to contain only one cleavage site for factor Xa (i.e. at
Arg320, rMZ-II) and is stable for several weeks at 4 °C (69) was activated
to produce rMZ-IIa. Thrombin time of normal human plasma in the
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FIGURE 3. A, comparison of the three forms of thrombin. The average clotting times
obtained in six different measurements in the presence of 10 nM enzyme are shown as
follows: white, ␣-thrombin; black, ␤-thrombin; and hatched, rMZ-IIa. B, comparison of the
activity of the peptides. The average clotting time found in three different measurements in prothrombin-deficient plasma are shown as follows: A, 25 nM prothrombin; B,
25 nM rMZ-II; C, 25 nM prothrombin that was preincubated with 250 M D5Q1,2; D, 25 nM
prothrombin that was preincubated with 250 M P15H; E,100 nM rMZ-II; F, 100 nM rMZ-II
that was preincubated with 250 M D5Q1,2; G, 25 nM prothrombin that was preincubated with 50 M Hir54 – 65; H, 25 nM prothrombin that was preincubated with 50 M
Hir55– 65(SO⫺
3 ).

presence of 10 nM ␣-thrombin was 26 s, while under similar experimental conditions, thrombin time with ␤-thrombin was 160 s (Fig. 3A). A
similar thrombin time was obtained in a control experiment when
buffer was substituted for protein (170 ⫾ 12 s); thus, ␤-thrombin has
negligible clotting activity. An analogous experiment with rMZ-IIa
resulted in a thrombin time that was ⬃4-fold increased (97 s) corresponding to ⬃7% of the clotting activity of ␣-thrombin (Fig. 3A). These
data demonstrate that both ABEs of ␣-thrombin are required for timely
clot formation in whole plasma. However, ABE-I appears to be more
important for ␣-thrombin functions in whole plasma, because rMZ-IIa
promotes fibrinogen clotting faster than ␤-thrombin albeit less efficiently than ␣-thrombin.
Effect of Synthetic Peptides on Prothrombin Activity during Clotting—
We have previously shown that a pentapeptide from the COOH terminus of factor Va heavy chain inhibits thrombin and prothrombin functions, because it represents a thrombin/prothrombin binding exosite for
factor V and factor Va, respectively (DYDYQ, D5Q) (68). The pentapeptide contains two tyrosine residues that have the potential to be sulfated.
To ascertain the effect of tyrosine sulfation on the inhibitory potential of
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the pentapeptide, we obtained the double sulfated version of the pentapeptide, and we tested its ability to inhibit clotting in prothrombindeficient plasma. In Fig. 3B, bars A, B, and E show control clotting times
obtained when 25 nM prothrombin, 25 nM rMZ-II, and 100 nM rMZ-II,
respectively, were added to prothrombin-deficient plasma. In the presence of 250 M D5Q1,2 the clotting time of prothrombin and rMZ-II
was increased 3-fold (bars C and F, respectively). This effect of D5Q1,2
was similar to effect observed with non-sulfated hirudin (Hir54 – 65, bar
G) but was 2-fold lower than the effect produced by sulfated hirudin
(Hir55– 65(SO⫺
3 ), bar H). Overall the data demonstrate that D5Q1,2 is a
potent inhibitor of ␣-thrombin and prothrombin functions in whole
plasma.
Effect of D5Q1,2 on Procofactor Cleavage by ␣-Thrombin—Based on
several previous observations suggesting that activation of factor V and
factor VIII requires the integrity of both ABEs of thrombin (32, 33), we
initiated a series of studies on the cleavage and activation of factor V and
factor VIII by ␣-thrombin and ␤-thrombin to ascertain the contribution
of each of the two ABEs separately to procofactor cleavage and activation. We have also evaluated the inhibitory effect of D5Q1,2 on all
enzymes studied. Fig. 4A, lanes 2–9, show that, under the conditions
employed, factor V activation by ␣-thrombin is complete by 15 min.
Preincubation of ␣-thrombin with 100 M D5Q1,2 resulted in considerable decrease of the rate of cleavage at Arg709 while cleavage at Arg1545
was almost completely abrogated (Fig. 4B). Similar results were found
with the non-sulfated version of the peptide however, the non-sulfated
peptide was less effective in inhibiting factor V activation under similar
experimental conditions (not shown). Analogous experiments conducted with ␤-thrombin in the absence of D5Q1,2 demonstrated slow
cleavage at Arg709 while cleavage at Arg1545 did not occur during the
time interval studied (Fig. 5A, lanes 2–9). Following incubation of
␤-thrombin with D5Q1,2, slight inhibition of cleavage at Arg709 was
observed (Fig. 5B, lanes 2–9). Overall our findings provide evidence for
the requirement of ABE-I of ␣-thrombin for timely cleavage at Arg1545
of factor V. This cleavage that results in the formation of the light chain
of factor Va, is rate-limiting during activation of factor V and is required
for expression of optimal cofactor activity. Thus, ␣-thrombin interaction with factor V through ABE-I is required for cleavage of the procofactor at Arg1545 and expression of optimum cofactor activity.
We next assessed the effect of ␣- and ␤-thrombin on factor VIII
activation (Fig. 6). Under the conditions employed, factor VIII was
cleaved by ␣-thrombin at all three activating cleavage sites to produce
the expected fragments (Fig. 6A). Although ␤-thrombin cleaved factor
VIII slowly at Arg740 to produce the Mr 90,000 heavy chain (Fig. 6B,
lanes 2– 8), the enzyme was unable to cleave factor VIII at Arg372 and
Arg1689 (Fig. 6B, lanes 2– 8). These two latter cleavages are required
for procofactor activation (16 –18). Cleavage at Arg372 and Arg1689
occurred readily following incubation of the ␤-thrombin-cleaved procofactor with ␣-thrombin (Fig. 6B, lane 9). These data demonstrate
requirement of ABE-I for factor VIII activation. Factor VIII activation
by ␣-thrombin was severely inhibited by D5Q1,2 because of impaired
cleavage at all three sites. However, cleavages at Arg372 and Arg1689 by
␣-thrombin were more susceptible to inhibition by the sulfated pentapeptide than cleavage at Arg740 (Fig. 6C). The non-sulfated peptide
inhibited ␣-thrombin activation of factor VIII albeit less efficiently (not
shown). Fig. 6D shows that cleavage of factor VIII by ␤-thrombin at
Arg740 was also inhibited by D5Q1,2. Overall, the data demonstrate that,
like factor V activation, the two required factor VIII-activating cleavages
necessitate the integrity of ABE-I. Altogether, our findings suggest that
exposure of ABE-I alone is required and sufficient for efficient cleavage
and activation of both procofactor molecules.
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FIGURE 4. Effect of D5Q1,2 on factor V activation by ␣-thrombin. A, activation of factor V (500
nM) by ␣-thrombin alone (2 nM). Factor V was
incubated with ␣-thrombin as described under
“Experimental Procedures.” B, ␣-thrombin was preincubated with D5Q1,2, and the mixture was added
to factor V. At selected time intervals, aliquots of the
mixtures were removed, mixed with 2% SDS, heated
for 5 min at 90 °C, and analyzed on a 4 –12% SDSPAGE followed by immunoblotting. Fragments
were identified following staining with a mixture
of monoclonal antibodies ␣HFV#17 that recognizes an epitope between amino acid residues
307–506 of factor V and ␣HFV#9 that recognizes
an epitope on the light chain of the active cofactor. Immunoreactive bands were visualized with
chemiluminescence. Lane 1 in both panels depicts
aliquots of the mixture withdrawn from the reaction before the addition of thrombin or ␣-thrombin/peptide mixture, whereas lanes 2–9 show aliquots of the reaction mixture withdrawn at 30 s, 1
min, 5 min, 10 min, 15 min, 30 min, 1 h, and 2 h
following the addition of ␣-thrombin alone or of
␣-thrombin/peptide mixture. The positions of the
light and heavy chain of factor V as well as of single
chain factor V are indicated at the right (for more
details refer to Fig. 1).

FIGURE 5. Effect of D5Q1,2 on factor V activation by ␤-thrombin. A, activation of factor V (500
nM) by ␤-thrombin alone (2 nM). Factor V was incubated with ␤-thrombin as described under
“Experimental Procedures.” B, ␤-thrombin was
preincubated with D5Q1,2, and the mixture was
added to factor V. At selected time intervals, aliquots of the mixtures were removed and treated
as described in the legend to Fig. 4. Lane 1 in both
panels depicts aliquots of the mixture withdrawn
from the reaction before the addition of thrombin
or thrombin/peptide mixture, whereas lanes 2–9
show aliquots of the reaction mixture withdrawn
at 30 s, 1 min, 5 min, 10 min, 15 min, 30 min, 1 h,
and 2 h following the addition of thrombin alone
or of ␤-thrombin/peptide mixture. Lane 10 in both
panels represents an aliquot of the mixture shown
in lane 9 treated with ␣-thrombin for an additional
10 min. The positions of the light and heavy chains
of factor V as well as of single chain factor V
are indicated at the right (for more details refer
to Fig. 1).

Activation of Factor V and Factor VIII by Meizothrombin—To ascertain if exposure of ABE-I alone is sufficient for efficient procofactor
activation we used rMZ-IIa. Meizothrombin has been reported to
cleave and activate factor V only in the presence of a membrane surface
(47, 49). The data obtained herein demonstrate that factor V is readily
cleaved and activated by membrane-bound rMZ-IIa (Fig. 7A). Factor V
activation by membrane-bound rMZ-IIa was completely abrogated by
D5Q1,2 because of impaired cleavages at Arg709, Arg1018, and Arg1545
(Fig. 7B). Direct comparison of the rates of cleavage of membranebound factor V by ␣-thrombin and meizothrombin revealed that, under
similar experimental conditions, meizothrombin cleaves membranebound factor V with a rate that is 5-fold faster than the rate of cleavage
of the membrane-bound procofactor by ␣-thrombin (not shown).
Overall the data demonstrate that amino acids from ABE-I interact with
factor V in order for the molecule to be efficiently cleaved at all three
sites by membrane-bound rMZ-IIa. Thus, exposure of ABE-II is not
required and does not appear to play any significant role in factor V
activation.
We next assessed the capability of membrane-bound rMZ-IIa to
cleave and activate recombinant human factor VIII. Activation of the
procofactor by membrane-bound rMZ-IIa occurred readily during a
20-min incubation period (Fig. 8A, lanes 1– 8). Cleavage and activation
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of factor VIII by membrane-bound rMZ-IIa was completely inhibited by
100 M D5Q1,2 (Fig. 8B, lanes 1– 8). Even cleavage at Arg740 by membrane-bound rMZ-IIa was susceptible to inhibition by the sulfated
pentapeptide. This cleavage was partially resistant to inhibition
when using ␣-thrombin (see Fig. 6C). These data demonstrate that
membrane-bound rMZ-IIa is more sensitive to D5Q1,2 inhibition
than ␣-thrombin.
Activation of factor V during Clot Formation—Our data suggest that
meizothrombin is a potent activator of both procofactors. However,
while extensive data in the literature provides evidence that meizothrombin is impaired in its fibrinogen-clotting activity, no data have
been yet reported assessing the clotting activity of meizothrombin in
prothrombin-deficient plasma.
To assess the activity of meizothrombin in whole plasma, a previously
described modified clotting assay was employed (66). When PCPS vesicles and CaCl2 were added to normal plasma, clotting was observed in
35 min. Under similar experimental conditions, where prothrombindeficient plasma was complemented with rMZ-II, clotting also occurred
following ⬃35-min incubation (Fig. 9, vertical arrows). Fig. 9A depicts
products from factor V formed during the experiment prior and after
clot formation. Clot formation in both cases correlates with appearance
of both the heavy and light chains of factor Va. Prolonged incubation of

VOLUME 281 • NUMBER 27 • JULY 7, 2006

Role of ABE-I for Factors V and VIII Activation

FIGURE 6. Effect of D5Q1,2 on factor VIII activation by ␣- and ␤-thrombin. A, activation of factor
VIII (500 nM) by ␣-thrombin alone (2 nM). B, activation
of factor VIII (500 nM) by ␤-thrombin alone (2 nM). C,
␣-thrombin was preincubated with D5Q1,2, and the
mixture was added to factor VIII. D, ␤-thrombin was
preincubated with D5Q1,2, and the mixture was
added to factor VIII. At selected time intervals, aliquots of the mixtures were removed mixed with 2%
SDS, 2% ␤-mercaptoethanol, heated for 5 min at
90 °C, and analyzed on a 5–15% SDS-PAGE followed
by staining with Coomassie Blue. Lane 1 in all panels
depicts aliquots of the mixture withdrawn from the
reaction before the addition of thrombin or thrombin/peptide mixture, whereas lanes 2– 8 show aliquots of the reaction mixture withdrawn at 30 s, 1
min, 3 min, 5 min, 10 min, 15 min, and 20 min following the addition of thrombin alone or of thrombin/
peptide mixture. Lane 9 in B and D is an aliquot of the
mixture at 20 min treated with ␣-thrombin for an
additional 10 min. The positions of all factor VIII fragments are indicated at the right (for more details
refer to Fig. 1).

FIGURE 7. Effect of D5Q1,2 on factor V activation by meizothrombin. A, activation of factor V
(500 nM) by membrane-bound rMZ-IIa (2 nM). B,
membrane-bound meizothrombin was preincubated with D5Q1,2, and the mixture was added to
factor V. At selected time intervals, aliquots of
the mixtures were removed and treated as
described in the legend to Fig. 4. Lane 1 in both
panels depicts aliquots of the mixture withdrawn
from the reaction before the addition of rMZIIa or
rMZIIa/peptide mixture; whereas lanes 2– 8 show
aliquots of the reaction mixture withdrawn at 30 s,
1 min, 3 min, 5 min, 10 min, 15 min, and 20 min
following the addition of rMZ-IIa alone or of rMZIIa/peptide mixture. The positions of the light and
heavy chains of factor V as well as of single chain
factor V are indicated at the right (for more details
refer to Fig. 1).

the samples at 37 °C results in the appearance of fragments of Mr 75,000,
54,000, and 30,000 characteristic of the degradation of factor Va heavy
chain by intrinsically formed activated protein C (APC) (2, 66, 67). Surprisingly, when prothrombin-deficient plasma is supplemented with
physiological concentrations of rMZ-II the heavy chain of factor Va
appears to be significantly more degraded than the factor Va heavy
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chain obtained in normal plasma (compare in Fig. 9A, lanes 14 and 7,
respectively). Scanning densitometry demonstrated that when prothrombin-deficient plasma is incubated with plasma prothrombin, 85%
of the heavy chain remains following 60-min incubation (Fig. 9A, lane
7). In contrast, when prothrombin-deficient plasma is supplemented
with rMZ-II, only 35% of the heavy chain remains following 60-min
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FIGURE 8. Effect of D5Q1,2 on factor VIII activation by meizothrombin. A, activation of factor
VIII (500 nM) by membrane-bound rMZ-IIa (2 nM).
B, membrane-bound meizothrombin was preincubated with D5Q1,2, and the mixture was added
to factor VIII. At selected time intervals, aliquots of
the mixtures were removed and treated as
described in the legend to Fig. 6. Lane 1 in both
panels depicts aliquots of the mixture withdrawn
from the reaction before the addition of rMZIIa or
rMZIIa/peptide mixture, whereas lanes 2– 8 show
aliquots of the reaction mixture withdrawn at 30 s,
1 min, 3 min, 5 min, 10 min, 15 min, and 20 min
following the addition of rMZ-IIa alone or of rMZIIa/peptide mixture. The positions of the light and
heavy chains of factor VIII are indicated at the right
(for more details refer to Fig. 1).

incubation. A logical explanation for this significant difference in the
degradation of factor Va heavy chain, can be provided by the fact that
under the experimental conditions employed more APC is generated
following clot formation by meizothrombin than by ␣-thrombin. These
data are in total agreement with previous kinetic studies (48) and demonstrate for the first time that, in whole plasma, meizothrombin is a
better activator of protein C in the presence of PCPS than ␣-thrombin.
Data shown in Fig. 9B demonstrate that clotting coincides with the
formation of thrombin (arrows). Overall, our findings establish meizothrombin as a potent procoagulant and verify the fact that, in the presence of a procoagulant membrane surface, and in the absence of thrombomodulin (TM), meizothrombin is a more efficient anticoagulant than
␣-thrombin with respect to protein C activation and factor Va heavy
chain cleavage.
Molecular Dynamics Simulations of the Inhibitory Peptides—In addition to all the data thus far presented, we have identified D5Q1,2 as a
potent inhibitor of ␣-thrombin. The peptide appears to interact with
ABE-I of the enzyme impairing several ABE-I-related functions. Sulfation of D5Q on both tyrosines significantly increases its potency with
respect to ␣-thrombin inhibition when compared with the non-sulfated
peptide (68). To ascertain the differences in peptide conformation following sulfation of D5Q, a 50-ns molecular dynamics simulation of the
peptides in aqueous solution was performed, and snapshots of each
molecule are shown in Fig. 10. Although the distance between the ␣
carbon of Asp1 and the ␣ carbon of Gln5 was always greater than 1 nm,
D5Q was found to interchange conformations periodically between a
linear and a packed conformation. In ⬃40% of the simulation time, D5Q
adopted a packed conformation with Tyr2 and Tyr4 facing each other
(see Fig. 10A). Although the distance between the hydroxyl groups of
Tyr2 and Tyr4 varies between 3.5 and 5 Å, which is approximately twice
the minimal distance allowed for a typical hydrogen bond to occur
(⬃1.8 Å), the packed conformation appeared to be the preferred conformation for D5Q approximately half the time in solution. Thus, the
fact that the two phenyl groups in D5Q face each other periodically, may
explain the insolubility problems encountered when working with high
concentrations of D5Q. In contrast, D5Q1,2 preferred a linear rather
than a packed conformation (Fig. 10B). D5Q1,2 was found in the latter
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conformation only 1% of the total simulation time. In addition, no solubility problems were encountered when working with D5Q1,2. The
data suggest that the two sulfate moieties in D5Q1,2 are repulsive leading to an open conformation most of the time, which in turn, must favor
interaction of D5Q1,2 with ␣-thrombin compared with D5Q. Moreover, D5Q1,2 has two additional negative charges that can interact with
basic amino acids from ABE-I of ␣-thrombin and meizothrombin. In
sum, D5Q1,2 has an advantage over D5Q, because it possesses overall
more negative charges available to interact with more positive charges
from ABE-I of ␣-thrombin. All these facts may explain the increased
potency for inhibition of ␣-thrombin function by D5Q1,2 when compared with inhibition of the enzyme by D5Q.

DISCUSSION
The data presented herein using natural and minimal modified
recombinant proteins demonstrate for the first time that: 1) exposure of
ABE-I of ␣-thrombin alone is required and sufficient for timely and
efficient activation of factor V and factor VIII; 2) a thrombin molecule
that has only ABE-II available is unable to efficiently cleave and activate
both procofactors; 3) membrane-bound meizothrombin can efficiently
cleave and activate factor VIII; 4) meizothrombin is a more efficient
activator of factor V than ␣-thrombin in the presence of a procoagulant
membrane surface; 5) membrane-bound meizothrombin, at the place of
vascular injury, can efficiently account for both clot initiation as well as
protein C activation (in the absence of TM); and 6) a sulfated pentapeptide mimicking an ␣-thrombin interactive site on factor V (D5Q1,2) is a
new ABE-I ligand that impedes ␣-thrombin function in whole plasma
and impairs activation of both procofactors. Collectively, the data presented in this report strongly support the notion that membrane-bound
meizothrombin can sustain initiation and termination of blood clotting
during normal hemostasis.
Human thrombin’s function is allosterically regulated through the
binding of Na⫹ (88 –91). The important amino acids for the expression
of thrombin’s sodium-induced allosteric regulation were identified
using 78 alanine mutants of thrombin (92). The fast form of thrombin
(bound to Na⫹) is procoagulant, because it cleaves fibrinogen more
efficiently than the slow form of the enzyme (Na⫹ free), which in turn is
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FIGURE 9. Proteolysis of factor V and prothrombin during clot formation. Normal plasma (lanes
1–7) was diluted 10-fold in a CaCl2-containing
buffer following by the addition of PCPS vesicles.
Prothrombin-deficient plasma (lanes 8 –14) was
also diluted 10-fold in a CaCl2-containing buffer,
supplemented with rMZ-II (140 nM) and clotting
was initiated with PCPS vesicles. Clotting in both
samples occurred at ⬃32 min (arrowheads on top).
Lanes 1 and 8 represent control samples prior to
the addition of PCPS vesicles. Lanes 2–7 and 9 –14
depict aliquots of the reaction mixture at 5, 15, 25,
35, 45, and 60 min following the addition of PCPS
vesicles. All samples were analyzed by SDS-PAGE
(4 –12% linear gradient) under non-reducing conditions followed by transfer to polyvinylidene
difluoride membranes. A, results of an immunoblot probed with a mixture of monoclonal antibodies to human factor Va (i.e. ␣HFV-17 that recognizes an epitope on the heavy chain of the
cofactor and ␣HFV-9 that recognizes an epitope
on the light chain of factor V (66)). The arrows at
right depict the position of single chain factor V
(FV ), the Mr 105,000 heavy chain of factor Va (HC),
the Mr 74,000 light chain of the cofactor (LC ), the
Mr 75,000 fragment deriving from cleavage of
the heavy chain at Arg506 (amino acids 1–506,
75,000APC), the Mr 30,000 fragment obtained from
cleavage of factor Va at Arg506/Arg306 (amino
acids 307–506, 30,000APC), and the Mr 54,000 fragment deriving from initial cleavage of the heavy
chain by APC at Arg306 amino acids (306 – 679,
54,000APC). The positions of the molecular weight
markers are indicated at the left. B, result of an
immunoblot probed with a polyclonal monospecific antibody to human prothrombin made in
sheep. The arrows at the right represent the position of fragment 1䡠2 (amino acids 1–271) and of
␣-thrombin.

considered to be the anticoagulant version of thrombin, because it activates protein C more efficiently (91). The fast form of human thrombin
specifically recognizes substrates such as factor V and factor VIII (33,
93). Recent data have shown that murine thrombin does not respond to
sodium regulation, because the enzyme is locked in a conformation that
favors the fast form (94).
It has been established that two cleavages in factor VIII (i.e. Arg372
and Arg1689) and one cleavage in factor V (i.e. Arg1545) are required for
expression of optimum cofactor activity. Both anion binding exosites of
thrombin were reported to be implicated in the cleavage and activation
of both procofactors (32, 33, 93, 95). Previous data using site-directed
mutagenesis suggested that, while the integrity of anion binding exosite
I represents a requirement for efficient proteolytic cleavage of factor
VIII at Arg372 and Arg1689, anion binding exosite II appears to have a
small contribution for the cleavage at Arg372. Alanine scanning
mutagenesis also assigned important roles for ABE-I, ABE-II, and the
Na⫹ binding site of thrombin for the activation of factor V. However,
the minimum structural determinants from thrombin, necessary for the
activation of both procofactors have not yet been determined.
Earlier data demonstrated that purified bovine ␤-thrombin (a natural
derivative of ␣-thrombin) can slowly cleave bovine factor V at Arg1006
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(equivalent to Arg1018 in the human molecule) (9). Further, cleavages at
Arg713 and Arg1536 (equivalent to Arg709 and Arg1545, respectively, in
human factor V) and formation of the heavy and light chains were
severely impaired when using ␤-thrombin, with cleavage at Arg1536
being almost completely resistant to ␤-thrombin (no light chain formation following a 20-min incubation period). Moreover, cleavage at
Arg713 and Arg1536 occurred readily following incubation of the
␤-thrombin-cleaved bovine procofactor with bovine ␣-thrombin (9).
Our data show that ␤-thrombin that has poor clotting activity and only
ABE-II available, is unable to cleave plasma-derived human factor V at
Arg1545 and recombinant factor VIII at Arg372 and Arg1689 but can promote cleavage at Arg709 in factor V and at Arg740 in factor VIII, albeit less
efficiently than ␣-thrombin. In contrast, meizothrombin, which unlike
␤-thrombin is impaired in all of ABE-II-related functions of ␣-thrombin, can efficiently cleave and activate both procofactors. Altogether,
the data suggest that, while both ABEs have been reported to be
involved in factor V and factor VIII activation to various degrees, amino
acids from ABE-I appear to be solely responsible and sufficient for the
primary interaction between the enzyme and the procofactors, thereby
controlling efficient activation. In addition, because purified human
␤-thrombin is a natural derivative of ␣-thrombin, all concerns relating
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FIGURE 10. Solution conformation of D5Q and D5Q1,2. Molecular dynamic simulations of the peptides were performed as described under “Experimental Procedures.”
The two panels show a representation with schematics and sticks for D5Q (A) and D5Q1,2
(B). Snapshots for both peptides were taken at 10 ns. The dotted yellow line in both panels
measures the length of the peptides between the C␣ of Asp1 and the C␣ of Gln5.

to conformational changes resulting in functional alterations that are
valid for recombinant proteins are not applicable to the ␤-thrombin
molecule used in this study. Overall, our findings assign a novel function
to ABE-I: interaction with amino acids from the a1 and a3 domains of
factor VIII and the b2 domain of factor V, which in turn are required for
cleavage and activation of both procofactors. Further, because ABE-I of
␣-thrombin is readily available in meizothrombin, our data are in agreement with previous and recently published work, suggesting that meizothrombin may be responsible for procofactor activation in vivo during
the critical initial steps of coagulation (46, 47, 49).
Complete knock-out of the TM gene causes embryonic lethality
before the assembly of a vascular system (96, 97). In addition, a mouse
model in which TM could not serve as a cofactor for thrombin for
protein C activation (TMPro/Pro) generated mice with increased intravascular fibrin deposition in some tissues, however, the mutant mice
remained free of thrombosis and exhibited normal life span (98, 99).
Further, the mutant mice failed to show any fibrin deposition in the
brain or kidney suggesting that anticoagulation could be regulated differently depending on the tissue (98). On the other hand, in vitro experiments have demonstrated that, in the presence of TM, thrombin and
meizothrombin have similar catalytic efficiencies with respect to APC
formation (48, 100, 101). However, in the presence of PCPS vesicles or a
cell surface, the catalytic efficiency of meizothrombin for the activation
of protein C is 6-fold higher than the activity of thrombin for the same
reaction (48, 101), and this increased efficiency is specifically due to the
binding of meizothrombin to the membrane surface, because meizothrombin desF1 has the same activity as thrombin for the activation of
protein C in the presence of TM and in the presence or absence of a
membrane surface (48). Our data show that, in whole plasma, in the
absence of TM but in the presence of PCPS vesicles, meizothrombin
generates APC much faster than thrombin as shown by the increase in
appearance of APC-degradation products from factor Va heavy chain.
Our findings thus provide a logical explanation for the fact that require-
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ment for TM may be bypassed during normal anticoagulation, locally at
the place of vascular injury by meizothrombin. Moreover, because
meizothrombin remains bound to the injured surface through its fragment 1 component, it is most likely that it will come in contact with
membrane-bound protein C as compared with thrombin that is free in
solution. Collectively, our findings strongly support the notion that
membrane-bound meizothrombin can initiate clotting and subsequent
protein C activation in the presence of a procoagulant membrane surface exposed following injury of the vessel wall.
The importance of initial cleavage of prothrombin at Arg320, resulting
in meizothrombin formation and total ABE-I exposure (55, 57, 69),
compared with that of cleavage at Arg271 alone, in vivo, is underscored
by the severity of symptoms of individuals heterozygous for prothrombin San Antonio, which are in sharp contrast with the milder symptoms
of homozygous and heterozygous individuals for prothrombin Dhahran, prothrombin Padua I, and prothrombin Barcelona (102–107). Prothrombin San Antonio has histidine instead of arginine at position 320
(102), prothrombin Dhahran and Padua I have histidine instead of arginine at position 271 (103–105), and prothrombin Barcelona has cysteine at position 271 (106, 107). Heterozygous individuals for prothrombin San Antonio have severe bleeding disorders following surgery or
trauma, while homozygous patients for prothrombin Barcelona and
Dhahran have mild to moderate bleeding episodes following challenge
(102, 103, 107). Thus, while the in vitro data suggest that ABE-I, which is
the primary binding site for fibrinogen, is fully exposed upon cleavage at
Arg320, all individuals having a circulating prothrombin molecule that is
unable to be cleaved at Arg271 have mild/moderate tendency to bleed
upon challenge (103–108). Nevertheless, the fact that all patients
with hypothrombinemia or dysprothrombinemia reported have some
detectable levels of thrombin-like activity in their plasma, suggest that
meizothrombin can assume the physiological functions of thrombin
albeit less efficiently, hence the mild to moderate bleeding tendency in
individuals homozygous for an amino acid substitution at Arg271 (108).
Data presented in this report verify this hypothesis and suggest that
membrane-bound meizothrombin can catalyze most reactions resulting in clot formation and/or clotting arrest and usually ascribed to
␣-thrombin, locally at the place of vascular injury, when an appropriate
membrane surface is provided. At this point it is important to emphasize the fact that considerable amounts of meizothrombin desF1 were
identified in human arterial and venous thrombi as well as in clotted
whole blood (109, 110). For this reason, although cleavage of prothrombin Dhahran, Barcelona, and/or Padua I at Arg320, which results in full
exposure of ABE-I and produces an active enzyme with reduced (but
not nil) fibrinogen clotting activity (because of exposure of ABE-I)
(55, 57, 69); only heterozygous patients with prothrombin San Antonio
were reported, and we can realistically speculate that homozygosity for
prothrombin San Antonio would be equivalent to complete prothrombin deficiency and thus incompatible with survival. Bearing all these
qualifications in mind, we must conclude that the scarcity of patient
data identifying mutations at Arg320 and Arg271 in prothrombin may
reflect the fact that homozygosity for the former is incompatible with
survival while heterozygosity for the latter may go undetectable. Thus,
the mild/moderate severity of the symptoms of individuals with a circulating prothrombin molecule that is unable to be cleaved at Arg271,
coupled to the abundance of prothrombin in plasma, will result in an
insignificant decrease of both the overall functional levels of prothrombin (i.e. thrombin and meizothrombin), and the bleeding phenotypes,
which in turn are the hallmark for patient detection (108).
Hirudin inhibits factor V activation and prothrombinase function
(29 –32, 111). Hirudin54 – 65 (or hirugen), a 12-amino acid peptide from
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the COOH-terminal portion of hirudin, also inhibits factor V activation
and cofactor function. Sulfation of hirugen on its unique tyrosine residue (Tyr63, Hir54 – 65(SO⫺
3 )) increased its potency with respect to thrombin/prothrombin interaction. However, Hir54 – 65(SO⫺
3 ) has ⬃100-fold
increased affinity for thrombin as compared with prothrombin (30, 56).
Further, the sulfated tyrosine was found to interact with ABE-I of
thrombin (112, 113). More recently, a mutant factor V molecule with
the sequence 695DYDY698 mutated to 695KFKF698 was found to be partially resistant to ␣-thrombin activation and a peptide with the sequence
DYDYQ impaired activation of single chain factor V by ␣-thrombin
(68). Data presented herein demonstrate that the double sulfated version of the peptide is a better inhibitor of ␣-thrombin function in plasma
when compared with the non-sulfated pentapeptide. This enhanced
potency is most likely the result of a more linear conformation of the
sulfated pentapeptide compared with the non-sulfated form, allowing
more contact points with ABE-I of ␣-thrombin. The accumulated data
also demonstrate that the amino acid motif E/DD adjacent to two critical activation cleavage sites in factor V and factor VIII are crucial for the
interaction of the molecules with ABE-I of meizothrombin/␣-thrombin
required for efficient procofactor activation. Inhibition of these points
of interaction may result in the inhibition of meizothrombin/␣-thrombin function in whole plasma and may thus represent a new anticoagulant molecule.
In conclusion, the physiological consequences in individuals with
natural prothrombin mutations together with data on record, and the
findings presented herein, establish meizothrombin and ABE-I of
thrombin as major players during the critical initial steps of the initiation/termination of blood coagulation. Our data also show that a sulfated pentapeptide inhibits several procoagulant ABE-I-related functions of ␣-thrombin and provide a target as well as the scaffold for the
synthesis of an exosite-directed anticoagulant molecule that could
inhibit and/or attenuate thrombin function in individuals with thrombotic tendencies.

14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.

Acknowledgments—We thank Dr. Lisa Regan from Bayer Corp. for the gift of
recombinant human factor VIII, and Dr. Ken Mann from the University of
Vermont for providing the monoclonal antibodies to factor V. The excellent
technical assistance of Kerri Smith is gratefully acknowledged. Finally we
thank Dr. Edward Plow from the Department of Molecular Cardiology at the
Cleveland Clinic Foundation for helpful advice and for critical reading of the
manuscript.

REFERENCES
1. Kalafatis, M., Egan, J. O., van’t Veer, C., Cawthern, K. M., and Mann, K. G. (1997)
Crit. Rev. Eukaryotic Gene Expression 7, 241–280
2. Mann, K. G., and Kalafatis, M. (2003) Blood 101, 20 –30
3. Nesheim, M. E., Taswell, J. B., and Mann, K. G. (1979) J. Biol. Chem. 254,
10952–10962
4. Krishnaswamy, S. (1990) J. Biol. Chem. 265, 3708 –3718
5. Krishnaswamy, S., Jones, K. C., and Mann, K. G. (1988) J. Biol. Chem. 263,
3823–3834
6. van Dieijen, G., Tans, G., Rosing, J., and Hemker, H. C. (1981) J. Biol. Chem. 256,
3433–3442
7. Rawal-Sheikh, R., Ahmad, S. S., Ashby, B., and Walsh, P. N. (1990) Biochemistry 29,
2606 –2611
8. Fay, P. J., and Koshibu, K. (1998) J. Biol. Chem. 273, 19049 –19054
9. Nesheim, M. E., Foster, W. B., Hewick, R., and Mann, K. G. (1984) J. Biol. Chem. 259,
3187–3196
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